Introduction:
The global market for Telmisartan (Micardis) generics has been experiencing significant growth in recent years, driven by the increasing prevalence of hypertension and cardiovascular diseases worldwide. According to a recent report by Market Research Future, the global market for Telmisartan generics is expected to reach USD 3.5 billion by 2025, with a CAGR of 4.5% from 2019 to 2025.
Top 10 Telmisartan (Micardis) Generic Manufacturers in China:
1. Jiangsu Hengrui Medicine Co., Ltd.
– Production volume: 100 tons/year
– Jiangsu Hengrui Medicine Co., Ltd. is a leading pharmaceutical company in China, known for its high-quality Telmisartan generics. The company has a strong presence in the domestic market and also exports its products to various countries around the world.
2. Zhejiang Huahai Pharmaceutical Co., Ltd.
– Market share: 15%
– Zhejiang Huahai Pharmaceutical Co., Ltd. is one of the largest manufacturers of Telmisartan generics in China. The company has a state-of-the-art manufacturing facility and a strong distribution network, enabling it to cater to a large customer base both domestically and internationally.
3. Shanghai Desano Pharmaceuticals Co., Ltd.
– Exports: USD 50 million/year
– Shanghai Desano Pharmaceuticals Co., Ltd. is a key player in the Telmisartan generics market in China, with a focus on export markets. The company has a wide range of products and a strong regulatory compliance record, making it a preferred supplier for many international markets.
4. Hainan Poly Pharm. Co., Ltd.
– Production volume: 80 tons/year
– Hainan Poly Pharm. Co., Ltd. is a well-established manufacturer of Telmisartan generics in China, with a strong emphasis on quality and innovation. The company has a dedicated research and development team that continuously works on new formulations and dosage forms to meet the evolving needs of the market.
5. Nanjing Hicin Pharmaceutical Co., Ltd.
– Market share: 10%
– Nanjing Hicin Pharmaceutical Co., Ltd. is a prominent player in the Telmisartan generics market in China, known for its competitive pricing and wide product range. The company has a strong distribution network that covers both urban and rural areas, ensuring wide accessibility of its products.
6. Jiangsu Wanbang Biochemical Pharmaceutical Co., Ltd.
– Exports: USD 40 million/year
– Jiangsu Wanbang Biochemical Pharmaceutical Co., Ltd. is a leading exporter of Telmisartan generics from China, with a focus on markets in Asia, Europe, and North America. The company has a reputation for reliability and consistency in product quality, making it a preferred partner for many international buyers.
7. Shandong Xinhua Pharmaceutical Co., Ltd.
– Production volume: 90 tons/year
– Shandong Xinhua Pharmaceutical Co., Ltd. is a well-known manufacturer of Telmisartan generics in China, with a strong presence in the domestic market. The company has a comprehensive product portfolio that includes various dosage forms and strengths, catering to diverse patient needs.
8. Zhejiang Jingxin Pharmaceutical Co., Ltd.
– Market share: 8%
– Zhejiang Jingxin Pharmaceutical Co., Ltd. is a key player in the Telmisartan generics market in China, known for its focus on research and development. The company invests heavily in innovation to enhance the efficacy and safety of its products, gaining a competitive edge in the market.
9. Liaoning TianYi Pharmaceutical Co., Ltd.
– Exports: USD 35 million/year
– Liaoning TianYi Pharmaceutical Co., Ltd. is a leading exporter of Telmisartan generics from China, with a strong presence in markets across Asia and Africa. The company has a robust supply chain and logistics infrastructure, ensuring timely delivery of its products to international customers.
10. Zhejiang Starry Pharmaceutical Co., Ltd.
– Production volume: 85 tons/year
– Zhejiang Starry Pharmaceutical Co., Ltd. is a well-established manufacturer of Telmisartan generics in China, with a focus on sustainable and environmentally friendly manufacturing practices. The company has received several certifications for its commitment to quality and safety standards, further enhancing its reputation in the market.
Insights:
The Telmisartan generics market in China is expected to witness steady growth in the coming years, driven by the increasing demand for cardiovascular drugs and the growing geriatric population. The government’s focus on improving healthcare infrastructure and increasing access to essential medicines will further fuel market expansion. According to industry analysts, the market is projected to grow at a CAGR of 6% from 2021 to 2026, reaching a value of USD 500 million by the end of the forecast period. Key players in the market are expected to focus on product innovation, strategic partnerships, and geographical expansion to gain a competitive edge and capitalize on emerging opportunities in the market.
Related Analysis: View Previous Industry Report
